Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02711410
Other study ID # NationalCardioCenterCognac
Secondary ID
Status Completed
Phase N/A
First received March 9, 2016
Last updated March 17, 2016
Start date October 2009
Est. completion date October 2015

Study information

Verified date March 2016
Source National Cerebral and Cardiovascular Center
Contact n/a
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Observational

Clinical Trial Summary

Background:

Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel. Recent studies, mostly done in cardiovascular patients, showed association of the CYP2C19 genotypes with recurrent cardiovascular events. However, prospective data on the impact of the genetic variants in stroke patients are limited.

Methods:

Five hundred and eighteen Japanese non-acute stroke patients treated with clopidogrel were registered at 14 institutions. Three CYP2C19 variants (CYP2C19*2, *3, *17) were genotyped and the patients were classified into three clopidogrel metabolizer groups inferred from the CYP2C19 genotypes: extensive (EM: *1/*1), intermediate (IM: *1/*2 or *1/*3), and poor (PM: *2/*2, *2/*3, or *3/*3). The CYP2C19*17 carriers were excluded from the analysis. The antiplatelet effects of clopidogrel were assessed by Adenosine diphosphate (ADP) -induced platelet aggregation and vasodilator-stimulated phosphoprotein (VASP) phosphorylation, expressed as VASP index. The endpoint was the composite incidence of stroke, transient ischemic attack, myocardial infarction, revascularization, other thromboembolic disease, or cardiovascular death during 2 years of follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 518
Est. completion date October 2015
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patients who had received long-term clopidogrel therapy (once a day for at least one month) with a minimum one-month interval between enrollment and the last cerebral ischemic or TIA event.

- Males and females aged 20 years or older who were prescribed clopidogrel for the secondary prevention of cerebral infarction or transient ischemic attack and who were willing and able to give written informed consent.

Exclusion Criteria:

- Malignancies

- Congenital bleeding tendency

- Atrial fibrillation

- Concomitant use of an oral anticoagulant agent

- a platelet count of < 100 x 109/L or > 450 x 109/L within 3 months of enrollment

- Modified rankin scale > 4

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Clopidogrel


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Cerebral and Cardiovascular Center

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome of the study was recurrent cardiovascular event (CVEs), including ischemic stroke, transient ischemic attack (TIA), acute myocardial infarction, urgent revascularization, other thromboembolic disease, and cardiovascular death. Ischemic stroke was defined as a new neurologic deficit of cardiovascular origin lasting at least > 24 hours based on radiological evidence of stroke. TIA was defined as a transient episode of neurologic dysfunction caused by focal brain ischemia and improving within 24 hours. Urgent revascularization was defined as emergent revascularization for unexpected hospitalization. Acute myocardial infarction was defined as myocardial cell necrosis in the setting of ischemic symptoms and electrocardiogram changes (ST segment elevation or depression, development of Q waves) and/or rising specific cardiac biomarkers. Cardiovascular death was defined as death due to stroke, myocardial infarction or documented sudden cardiac death. Two Years Yes
Secondary Secondary outcome was major bleeding (intracranial haemorrhage, documented retroperitoneal bleed, and any red blood cell transfusion rates or proportion with bleeding associated with a ?2g/dl hemoglobin drop). Intracranial haemorrhage retroperitoneal bleed were defined on radiological evidence. Proportion with bleeding associated with a ?2g/dl hemoglobin drop was assessed by Blood laboratory test. two years Yes
See also
  Status Clinical Trial Phase
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Recruiting NCT04796714 - AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE Phase 4
Completed NCT05278637 - GM03 - Platelet RNA Signatures of Aspirin Early Phase 1
Recruiting NCT03288441 - Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Recruiting NCT05306951 - Correct Timing of Head Imaging in Trauma
Recruiting NCT05732701 - Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions N/A
Recruiting NCT05702463 - Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II Phase 1
Not yet recruiting NCT03862651 - Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE) Phase 2
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4
Completed NCT00799396 - Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Phase 4
Completed NCT00325390 - Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Phase 3
Completed NCT04999293 - Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
Completed NCT04328883 - Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin Phase 1
Completed NCT02808767 - Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction Phase 4
Completed NCT00769938 - WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) Phase 4
Completed NCT03599284 - The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel Phase 2
Completed NCT03785509 - The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
Unknown status NCT01103843 - Plavix, Prasugrel and Drug Eluting Stents Pilot Trial N/A
Active, not recruiting NCT03462498 - ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS Phase 4